Related Experiment Videos

Hemangioendothelial sarcoma of the liver after thorotrast injection

Acta Pathologica Japonica
|September 1, 1981
PubMed

Insights

Thorotrast (Th-232) injection led to liver hemangioendothelial sarcoma 33 years later in an autopsy case. This rare cancer developed after significant radiation exposure from the contrast agent.

Area of Science:

  • Hepatobiliary pathology
  • Radiological oncology
  • Toxicology

Background:

  • Thorotrast, a radioactive contrast agent, was used for diagnostic imaging.
  • Long-term complications, including malignancy, are a concern following Thorotrast administration.

Observation:

  • Autopsy revealed liver hemangioendothelial sarcoma and capillary hemangiomas in a patient 33 years post-Thorotrast injection.
  • Histological examination confirmed extensive accumulation of Thorotrast material in liver and other organs.
  • The patient presented with abdominal swelling and jaundice, succumbing to hepatic failure.

Findings:

  • The absorbed radiation dose to the liver was calculated to be approximately 2,597 rads over 33 years.
  • Autoradiography and Th-232 activity measurements confirmed the presence of Thorotrast.
  • A direct correlation between Thorotrast exposure, radiation dose, and the development of liver sarcoma was established.

Implications:

  • This case highlights the significant long-term oncogenic risk associated with Thorotrast.
  • It underscores the importance of considering historical contrast agent use in diagnosing rare hepatic malignancies.
  • Further research into Thorotrast-induced carcinogenesis and monitoring protocols is warranted.

Related Concept Videos